Earlier this past week, the US Food and Drug Administration held a meeting with several states to discuss the section 804 importation program (SIP), which allows states and Indian tribes to import ...
After the close of stock markets on Friday, the Wall street Journal (WSJ) reported (here) that Director of the Center for Biologics Evaluation and Research (CBER), Dr Vinay Prasad, will leave the ...
According to J&J, this approval offers a potential new standard of care (SOC) as early as second line and brings a novel ...
Swiss pharma Roche (ROG: SIX) reported positive Phase II results for its investigational amylin analog petrelintide, showing meaningful weight loss and a placebo-like tolerability profile in people ...
US drugmaker Vertex Pharmaceuticals today announced data from a Phase IV study of Journavx (suzetrigine), a prescription ...
Swedish specialty pharma Orexo is reorganizing its management team as it pivots away from direct US commercialization ...
The Accelerating Clinical Trials in the EU (ACT EU) initiative has published a draft guidance document outlining how clinical ...
Cambridge, USA-based precision allosteric therapeutics biotech Atavistik Bio has announced the closing of a $40 million ...
Chinese cell therapy developer Lemang Biotech has raised nearly 200 million yuan ($28 million) in fresh financing to advance ...
French pharma Sanofi (Euronext: SAN) has agreed to license the experimental drug rovadicitinib from China’s Sino Biop (HKEX: 1177), paying $135 million upfront for exclusive development and ...
Germany’s Merck KGaA reported broadly stable full-year 2025 results, with modest top-line pressure from currency headwinds ...
Hangzhou Sciwind Biosciences, a biopharmaceutical company focused on the discovery and development of innovative therapies for metabolic diseases, today announced that China's National Medical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results